The larger tumors in males with higher prolactin levels suggest that the size discrepancy in tumors between sexes is not primarily due to a diagnostic delay, but rather reflects gender-related differences in tumor behavior, potentially involving the estrogen receptor pathway [27,31]. This evidence concerns the gene ESR1 and neoplasm.